FOLH1 and prostate carcinoma: Ga-68 PSMA-11 was found to be significantly better at detecting prostate cancer recurrence than Axumin in patients with early biochemical recurrence after prostatectomy, with the exception being locoregional recurrence where Axumin was more sensitive due to its lack of radiotracer in the bladder [15,16].